Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

EU approves Simbrinza for Glaucoma and Ocular Hypertension-Alcon/Novartis

29-Jul-2014

Alcon has announced that Simbrinza ...

AstraZeneca and Roche collaborate to develop diagnostic test for AZD 9291

29-Jul-2014

AstraZeneca announced it has ...

AstraZeneca and Qiagen collaborate to develop diagnostic test for Iressa in NSCLC.

29-Jul-2014

AstraZeneca announced that it has ...

EC approves Envarsus for Kidney/Liver Transplant Rejection-Veloxis Pharma

29-Jul-2014

The European Commission (EC) has ...

Results from COSMOS study of Olysio + Sovaldi for HCV published in The Lancet-Medivir

29-Jul-2014

Medivir has announced that results ...

CHMP recommends Accofil for treatment of Neutropenia- a biosimilar version of Neupogen-Accord HealthCare

29-Jul-2014

On 24 July 2014, the Committee for ...

3C study of Campath for Transplant Rejection published in The Lancet-Sanofi/Genzyme

29-Jul-2014

Results of the 3C study of Campath - ...

Recent Updates

Drugs

Clinical Guidelines

Management of epithelial ovarian cancer

Antibiotic Prophylaxis in Gastrointestinal Endoscopy

Management of cancer pain: ESMO Clinical Practice Guidelines

Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation

Medical Journals

Incorporation of Bovine-based Structural Bone Grafts Used in Reconstructive Foot Surgery

Who Should We Trust in Screening for Lower Urinary Tract Dysfunction in Children: The Parents or the Child?

Influence of strength training variables on strength gains in adults over 55 years-old: A meta-analysis of dose–response relationships

Complex assessment of age-specific morphofunctional features of skin of different anatomic localizations

epgonline.org Social